Free tool
FAERS Monitor: Xipere
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211950 or its brand name (Xipere, Triamcinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
24,536
Serious
13,112
53% of reports
Hospitalization
6,275
Death reported
3,174
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,821
- off label use2,879
- pruritus2,715
- rash2,558
- pain2,133
- fatigue2,033
- nausea1,945
- product use in unapproved indication1,739
- diarrhoea1,704
- vomiting1,703
- condition aggravated1,678
- headache1,621
- arthralgia1,546
- dizziness1,438
- infusion related reaction1,419
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 71 |
| 2005 | 58 |
| 2006 | 40 |
| 2007 | 80 |
| 2008 | 116 |
| 2009 | 109 |
| 2010 | 113 |
| 2011 | 177 |
| 2012 | 175 |
| 2013 | 203 |
| 2014 | 227 |
| 2015 | 465 |
| 2016 | 633 |
| 2017 | 802 |
| 2018 | 1,050 |
| 2019 | 1,206 |
| 2020 | 1,470 |
| 2021 | 1,789 |
| 2022 | 2,312 |
| 2023 | 2,747 |
| 2024 | 3,545 |
| 2025 | 3,865 |
| 2026 | 3,283 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,623 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 1,419 | 18.7 | 17.8 | 23,363 |
| pruritusSignal | 2,715 | 6.1 | 5.9 | 11,682 |
| product use in unapproved indicationSignal | 1,739 | 6.1 | 5.8 | 7,361 |
| rashSignal | 2,558 | 5.1 | 4.9 | 8,441 |
| condition aggravatedSignal | 1,678 | 4.8 | 4.5 | 5,012 |
| arthralgiaSignal | 1,546 | 3.2 | 3.0 | 2,368 |
| vomitingSignal | 1,703 | 3.1 | 3.0 | 2,487 |
| painSignal | 2,133 | 3.0 | 2.9 | 2,885 |
| off label useSignal | 2,879 | 2.8 | 2.7 | 3,527 |
| drug ineffectiveSignal | 3,821 | 2.5 | 2.4 | 3,621 |
| dizzinessSignal | 1,438 | 2.5 | 2.4 | 1,290 |
| diarrhoeaSignal | 1,704 | 2.3 | 2.2 | 1,239 |
| fatigueSignal | 2,033 | 2.2 | 2.2 | 1,447 |
| headacheSignal | 1,621 | 2.2 | 2.1 | 1,115 |
| nauseaSignal | 1,945 | 2.1 | 2.0 | 1,175 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.